U.S. Renewable Energy Stock News

Virtu Financial (NYSE:VIRT) has joined zerohash's liquidity ecosystem as a market-making partner. The company is providing liquidity across zerohash's central limit order book and request for quote systems. The move connects Virtu's market-making capabilities with a growing digital asset infrastructure provider. For you as an investor, this move ties a traditional electronic market maker directly into a digital asset venue. Virtu Financial focuses on market making and trade execution across...

If you are wondering whether F&G Annuities & Life is attractively priced or just looks cheap on the surface, its recent share performance gives a few clues worth unpacking. The stock last closed at US$27.08, with a 10.1% gain over the past month but a 9.0% decline over the last year and a 9.9% decline year to date, which may leave you questioning whether sentiment or fundamentals are in the driving seat. Recent coverage of F&G Annuities & Life has focused on its position as a listed insurer...

Plains GP Holdings FY 2025 earnings recap Plains GP Holdings (PAGP) has just wrapped up FY 2025 with fourth quarter revenue of US$10.6 billion and a basic EPS loss of US$0.20, as investors weigh these headline figures against a current share price of US$23.63. Over recent quarters the company has seen revenue move between US$10.6 billion and US$12.5 billion. Basic EPS has ranged from a loss of US$0.44 in late 2024 to a small profit of US$0.04 in Q3 2025. This sets the stage for a close look...

If you are wondering whether Amdocs stock is starting to look like value or a value trap, the current share price puts that question front and center. The stock closed at US$65.14 recently, with returns of 0.7% over 7 days, a 1.9% decline over 30 days, an 18.7% decline year to date and a 27.6% decline over the last year. This naturally raises questions about how the market is reassessing both growth potential and risk. Recent coverage has focused on how Amdocs fits into broader shifts in...

Wondering if Adecoagro's recent share price puts it at a bargain or already reflects its strengths? This article breaks down what the current valuation is really telling you. The stock last closed at US$13.37, with a 72.3% return year to date and a 59.0% return over the past year. This is set against shorter term pullbacks of 5.1% over 7 days and 11.0% over 30 days that may signal shifting sentiment around risk and reward. Recent news around global food supply resilience, agricultural input...

If you are wondering whether MaxLinear's recent share price move has left the stock looking expensive or still potentially interesting, the valuation story is where your attention should be. The stock last closed at US$82.37, with returns of 16.4% over 7 days, 347.4% over 30 days, 345.0% year to date and a very large 1 year gain that is more than 6x. These moves sit against a backdrop of ongoing interest in semiconductor stocks, with investors watching closely for updates on demand for...

Why the upcoming TN-401 data matters for Tenaya Therapeutics stock Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting. This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline...

AGI (NYSE:AGBK) has filed a substantial Shelf Registration tied to an Employee Stock Ownership Plan for a large block of Class A common shares. The filing outlines a framework for issuing ESOP related shares over time, which can influence the company’s capital structure and employee ownership levels. AGI, trading at $7.39, has had mixed recent performance, with the stock up 4.2% over the past week and 9.5% over the past month, while showing a 31.3% decline year to date. The new ESOP related...

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...

Digi International acquired Jolt Software and Particle Industries, reshaping its Internet of Things (IoT) offering. The company reports that these deals, combined with organic growth, have lifted annual recurring revenue (ARR) by 50%. Management highlights strong cash flow as a key support for integrating these acquisitions into the existing business. Digi International (NasdaqGS:DGII) is drawing fresh attention as it leans harder into IoT platforms and recurring software revenue. The stock...

Main Street Capital (MAIN) has wrapped up FY 2025 with fourth quarter revenue of US$145.5 million and basic EPS of US$1.46. This sets the tone for a year in which trailing twelve month revenue reached US$566.4 million and EPS was US$5.52. Over recent periods, the company has reported quarterly revenue ranging between US$137.0 million and US$145.5 million, while basic EPS has moved between US$1.31 and US$1.46. Trailing net income for the year was US$493.4 million, as investors weigh those...

Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how...

If you are wondering whether Gilat Satellite Networks at around US$18.84 is priced for opportunity or disappointment, the starting point is to understand what the current valuation is really implying. The stock has posted returns of 2.1% over the last 7 days and 2.2% over the last 30 days, with year to date returns of 40.5% and a 1 year return of 189.0%, alongside a 3 year return of 243.2% and a 5 year return of 119.8%. Recent news flow around Gilat Satellite Networks has focused on its...

Wondering if Aptiv's current share price reflects its true worth, or if the recent swings are masking a clearer story about value. Aptiv closed at US$57.11, with returns of a 5.2% decline over 7 days, a 1.9% decline over 30 days, a 27.2% decline year to date, but a 10.3% gain over the past year, which can leave the stock looking quite different depending on the time frame you focus on. Those mixed returns sit against a backdrop of ongoing attention on Aptiv as an auto components supplier, as...

Geospace Technologies (GEOS) opened Q1 2026 with revenue of US$25.6 million and a basic EPS loss of US$0.76, alongside a trailing twelve month basic EPS loss of US$2.17 on revenue of US$99.2 million. Over recent quarters the company has reported revenue between US$18.0 million and US$37.2 million, while EPS has ranged from a profit of US$0.66 per share in Q1 2025 to several loss-making quarters since. For investors, that mix of fluctuating topline and persistent losses keeps the attention on...

Janus Henderson Group (JHG) closed out FY 2025 with fourth quarter revenue of US$1.1 billion and basic EPS of US$2.64, capping a trailing twelve month net income of US$798.3 million on basic EPS of US$5.25. Over the past year, total revenue has moved from US$2.5 billion on trailing basic EPS of US$2.57 to US$3.1 billion on trailing basic EPS of US$5.25, alongside an improvement in net profit margin from 16.1% to 25.8%. This puts earnings quality front and center for investors assessing the...

Assertio Holdings (ASRT) closed out FY 2025 with Q4 revenue of US$13.5 million and basic EPS of a US$1.86 loss, alongside a trailing twelve month revenue base of US$118.7 million and basic EPS of a US$4.74 loss. Over the past year, quarterly revenue has moved between US$26.5 million and US$49.5 million, while quarterly basic EPS has ranged from a US$2.56 loss to US$1.78, leaving investors focused on how these shifts are feeding through to underlying margins. See our full analysis for Assertio...

SIFCO Industries (SIF) opened Q1 2026 with total revenue of US$24.0 million and net income of US$1.8 million, translating to basic EPS of US$0.29 for the quarter. The company has seen quarterly revenue move from US$21.7 million in Q4 2024 to US$20.9 million in Q1 2025 and then to US$24.0 million in Q1 2026. Basic EPS shifted from a loss of US$0.25 in Q4 2024 and US$0.40 in Q1 2025 to a profit of US$0.29 in the latest period. This sets up an earnings season in which investors are likely to...

Token Cat (TC) has just posted its H1 2025 numbers, with revenue of C¥19.8 million and a net income loss of C¥0.7 million, translating to basic EPS of C¥5.74 loss per share, while trailing 12 month figures show revenue of C¥36.6 million and a net loss of C¥148.0 million, or C¥1,200.49 loss per share. Over recent half year periods the company has seen revenue move from C¥32.3 million in H1 2024 to C¥16.9 million in H2 2024 and then to C¥19.8 million in H1 2025. Over the same periods, EPS...

Afya (NasdaqGS:AFYA) reports revenue and EBITDA growth, highlighting resilient financial performance in its latest earnings update. The Medical Practice Solutions segment faces pressure from declining active payers and stronger competition from AI driven tools. These developments point to a mixed picture for Afya, with solid headline results and emerging challenges beneath the surface. Afya operates across medical education and healthcare services in Brazil, and its latest report underlines...

If you are wondering whether Arrowhead Pharmaceuticals at around US$77.95 is still offering value or has already run too far, this breakdown is designed to help you frame that question clearly. The stock has returned 6.1% over the past week, 27.4% over the last 30 days, 15.0% year to date, and 488.3% over the past year, which naturally raises questions about how much of the story is already priced in. Recent coverage has focused on Arrowhead Pharmaceuticals' progress in RNA interference...

If you are trying to work out whether LyondellBasell Industries' current share price reflects its underlying value, the recent moves in the stock give you plenty to think about. The stock closed at US$71.51, with a 4.1% decline over the past week and a 10.9% decline over the past month, yet it has returned 61.1% year to date and 36.5% over the last year. Recent coverage around LyondellBasell has focused on its position within the broader chemicals sector and how investors are weighing...

Navan (NasdaqGS:NAVN) has secured Criteo and Schindler as new enterprise clients for its AI-powered corporate travel platform. The agreements cover multi country travel programs and use Navan’s unified system for booking, policy compliance, and traveler support. Both clients are using Navan’s tools for operational efficiency, sustainability tracking, and user satisfaction across their global workforces. For investors watching corporate travel and expense software, Navan sits at the...

Legence (NasdaqGS:LGN) reported strong quarterly results, supported by organic growth across the business. The Installation & Maintenance segment delivered major outperformance within the period. Recent acquisitions were integrated into the business, contributing to current operations. Management raised 2026 guidance, signaling higher internal expectations for future performance. Legence, listed as NasdaqGS:LGN, focuses on installation and maintenance services, an area that can be closely...